Ginkgo Bioworks Reports 61% Revenue Jump in Q3 2024
Company Announcements

Ginkgo Bioworks Reports 61% Revenue Jump in Q3 2024

The latest update is out from Ginkgo Bioworks Holdings ( (DNA) ).

Ginkgo Bioworks reported a significant revenue increase of 61% in Q3 2024, primarily due to a $45 million non-cash deferred revenue release, despite a shift towards larger customers impacting cell engineering revenue. The company is advancing its strategic partnerships, including new deals with Novo Nordisk and Merck, and is focused on cost-cutting and site consolidation to achieve EBITDA breakeven by 2026. With the recent board changes, Ginkgo is poised to strengthen its position in the biosecurity market while enhancing its promising cell programming platform.

For detailed information about DNA stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyGinkgo Bioworks’s restructuring starting to bear fruit, says TD Cowen
TipRanks Auto-Generated NewsdeskGinkgo Bioworks Reports Q3 Growth and Strategic Deals
TheFlyClosing Bell Movers: Instacart down 6% after earnings
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App